-transparent.png){kind=logo}
A six- to eight-week double-blind placebo-controlled trial of the potent and selective serotonin reuptake inhibitor fluvoxamine was conducted in 42 patients with primary obsessive-compulsive disorder (OCD). Approximately one half of the patients also had symptoms of major depression. Fluvoxamine was significantly better than placebo on all measures of obsessive-compulsive symptoms. Nine of 21 patients were responders ("much improved") with fluvoxamine compared with no responders with placebo, and fluvoxamine was effective in patients with OCD both with and without secondary depression. Response of OCD was not correlated with severity of baseline depression. These data lend partial support to the serotonin hypothesis of OCD. However, since a number of patients failed to respond to fluvoxamine, the role of other neurochemical systems in this disorder needs to be explored.
W K Goodman, and
L H Price, and
S A Rasmussen, and
P L Delgado, and
G R Heninger, and
D S Charney
April 1996,
Journal of clinical psychopharmacology,
W K Goodman, and
L H Price, and
S A Rasmussen, and
P L Delgado, and
G R Heninger, and
D S Charney
March 1996,
International clinical psychopharmacology,
W K Goodman, and
L H Price, and
S A Rasmussen, and
P L Delgado, and
G R Heninger, and
D S Charney
July 1990,
The American journal of psychiatry,
W K Goodman, and
L H Price, and
S A Rasmussen, and
P L Delgado, and
G R Heninger, and
D S Charney
June 2003,
The Journal of clinical psychiatry,
W K Goodman, and
L H Price, and
S A Rasmussen, and
P L Delgado, and
G R Heninger, and
D S Charney
January 2005,
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology,
W K Goodman, and
L H Price, and
S A Rasmussen, and
P L Delgado, and
G R Heninger, and
D S Charney
December 2000,
Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists,
W K Goodman, and
L H Price, and
S A Rasmussen, and
P L Delgado, and
G R Heninger, and
D S Charney
March 2000,
International clinical psychopharmacology,
W K Goodman, and
L H Price, and
S A Rasmussen, and
P L Delgado, and
G R Heninger, and
D S Charney
November 2016,
Psychiatry and clinical neurosciences,
W K Goodman, and
L H Price, and
S A Rasmussen, and
P L Delgado, and
G R Heninger, and
D S Charney
October 2012,
CNS drugs,
W K Goodman, and
L H Price, and
S A Rasmussen, and
P L Delgado, and
G R Heninger, and
D S Charney
September 2023,
Psychiatry and clinical neurosciences,
